drugset / Trial / NCT05650320
To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients with AD
RandomizedParallel-groupDouble-blindTreatment
Summary
A multicenter, randomized, double-blind, vehicle-controlled, parallel group trial to demonstrate the superiority of 0.3% and 1% OPA-15406 ointment to vehicle in pediatric subjects with AD. This trial consists of the 0.3% OPA-15406 group, the 1% OPA-15406 group, and the vehicle group.
Timeline
- Start
- 2023-02-17
- Primary completion
- 2024-07-21
- Completion
- 2025-01-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Difamilast | Small molecule | 0.3 % | — |
| Subject | Difamilast | Small molecule | 1 % | — |